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Background: Non-invasive electrotherapy is commonly used for treatment of chronic low back pain. Evidence for
efficacy of most electrotherapy modalities is weak or lacking. This study aims to execute a high-quality, double-
blinded randomized controlled clinical trial comparing 1) H-WaveW Device stimulation plus usual care with 2)
transcutaneous electrical nerve stimulation (TENS) plus usual care, and 3) Sham electrotherapy plus usual care to
determine comparative efficacy for treatment of chronic non-specific low back pain patients.
Methods/Design: Patients- Chronic non-specific low back pain patients between ages of 18–65 years, with pain of
at least 3 months duration and minimal current 5/10 VAS pain. Patients will have no significant signs or symptoms
of lumbosacral nerve impingement, malignancy, spinal stenosis, or mood disorders.
Study design- Double blind RCT with 3 arms and 38 subjects per arm. Randomization by permuted blocks of
random length, stratified by Workers Compensation claim (yes vs. no), and use of opioids. The null hypothesis of
this study is that there are no statistically significant differences in functional improvement between treatment
types during and at the end of a 12-week week treatment period.
Data collection- Subjective data will be collected using Filemaker ProTM database management collection tools.
Objective data will be obtained through functional assessments. Data will be collected at enrollment and at 1, 4, 8,
and 12 weeks for each participant by a blinded assessor.
Interventions- H-WaveW device stimulation (Intervention A) plus usual care, transcutaneous electrical nerve
stimulation (TENS) (Intervention B) plus usual care, and sham electrotherapy plus usual care (control). Each
treatment arm will have identical numbers of visits (4) and researcher contact time (approximately 15 hours).
Outcomes- Primary outcome measure: Oswestry Disability Index. Secondary measures include: Rowland Morris
Instrument, VAS pain score, functional evaluation including strength when pushing and pulling, pain free range of
motion in flexion and extension. Outcome measures assessed at baseline, 1, 4, 8, and 12 weeks. Treatment failure
will be defined if patient terminates assigned treatment arm for non-efficacy or undergoes invasive procedure or
other excluded cointerventions. Data will be analyzed using intention-to-treat analysis and adjusted for covariates
related to LBP (e.g. age) as needed.
Discussion: Study strengths include complex randomization, treatment group allocation concealment, double
blinding, controlling for co-interventions, rigorous inclusion criteria, assessment of compliance, plans for limiting
dropout, identical assessment methods and timing for each treatment arm, and planned intention-to-treat analyses.
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Low Back Pain (LBP) is one of the most common rea-
sons for medical visits to physician offices and emer-
gency departments, with an estimated 61 Million visits
in 2007, up from an estimated 15 million visits in 1990
[1-3]. Chronic low back is associated with significant co-
morbidity and direct health care costs due to increased
health care utilization [4]. The economic burden of low
back pain is estimated between $20 and $50 billion annual
cost to the U.S. economy [5]. Additionally, low back injur-
ies result in an estimated 149 million lost workdays per
year and an additional $28 billion in productivity losses
[6]. Despite the relative pervasiveness of low back pain,
and the enormous financial burden on the health care sys-
tem, chronic low back pain remains a difficult condition to
treat [7,8]. Identification of efficacious noninvasive, non-
pharmacologic therapies could yield meaningful gains and
result in substantial population improvement in morbidity
and costs associated with LBP. A well-designed random-
ized trial is needed to determine comparative treatment
efficacy of electrical stimulation treatments that are rela-
tively inexpensive, noninvasive and nonpharmacologic.
Myriad treatments have been described for chronic
LBP, yet the body of quality randomized trials demon-
strating efficacy for many commonly used treatments is
limited [9-11]. A recent evidence based review demon-
strated that only 47 of 148 treatment interventions for
Chronic LBP have quality randomized trials as the basis
of recommendation for the intervention for low back
pain [8]. Thus, the majority of commonly used interven-
tions have little or no evidence of efficacy.
Specific to electrotherapy modalities, multiple devices
producing varying electronic waveform types, wave fre-
quency, and wave amplitude are used for analgesic relief
of chronic pain conditions, including nonspecific low back
pain. An evidence based review of electrotherapy literature
identified a modest number of moderate and low quality
trials that demonstrated evidence of transcutaneous elec-
trical nerve stimulation (TENS) efficacy for select patients
with chronic low back pain, however there is still no con-
sensus regarding efficacy of TENS for treating chronic
LBP [8,12-20]. Additionally, the reviews found insufficient
quality evidence for recommending for or against the use
of high-voltage galvanic therapy, interferential therapy,
iontophoresis, percutaneous electrical nerve stimulation
(PENS), microcurrent electrical stimulation, and sympa-
thetic electrotherapy for treating chronic low back pain.
Similarly, although there is strong anecdotal support,
there are no reported quality randomized controlled trials
demonstrating efficacy of the H-WaveW Device for symp-
tomatic relief of chronic low back pain. Regardless of the
evidence of efficacy of TENS in treating chronic LBP, it is
a common modality for treating LBP due to high demand
for noninvasive, nonpharmacologic interventions. It ishighly prescribed due to low cost and low occurrence of
side effects [21]. Identification of electrotherapy treat-
ments with quality evidence of efficacy, low cost, and low
adverse effect profile would be expected to result in im-
proved patient function, reduced pain, reduced morbidity,
improved productivity, and overall lower health care costs.
In this study, we evaluate anecdotal properties of the H-
Wave W device, which is reported to be highly efficacious
for many patients, and compares both economically and
in safety with achieved TENS treatment protocols.
The H-WaveW Device (Electronic Waveform Lab, Inc)
stimulation is an electrotherapy modality. The primary
difference between other electrotherapies and H-WaveW
is the waveform, with larger pulse durations and uni-
quely low frequencies. H-WaveW utilizes a bipolar ex-
ponentially decaying pulse with frequencies between
1-70Hz and a pulse duration of 5 milliseconds along
with some other proprietary factors. The H-WaveW de-
vice has received FDA clearance for a number of indica-
tions, including home-based treatment of chronic pain,
post-surgical pain, circulation, range of motion, and
muscle spasms. The mechanism(s) of action for the
H-WaveW Device are unique and include nitric-oxide
dependent enhanced microcirculation and angiogenesis,
stimulation and contraction of muscle fibers within the
subdermal lymphatic system, and deactivation of the so-
dium pump within the nerve fiber [22,23]. While the
exact mechanism of LBP treatment is unknown there
are multiple mechanisms, including the one that is refe-
renced above that may demonstrate efficacy for treating
LBP. Other mechanisms include stimulation of nocire-
ceptors and other nerve types to mask pain and allow
patients to improve function.
The intent of this trial is to execute a high-qualitya
double-blinded randomized controlled clinical trial that
compares the efficacy of the H-WaveW Device with a com-
monly used TENS device and with a control group using
a sham electrotherapy device [24]. A well-designed, high-
quality trial will provide definable level of evidence for
treatment efficacy, and provide a basis for evidence-based
recommendation for or against utilization of the use of
the H-WaveW device. The results for H-WaveW device, if
positive, could significantly impact morbidity by providing
a non-invasive, non-pharmacologic treatment for symp-
tomatic relief, and reduce overall disability and health care
costs associated with chronic low back pain.
Methods/Design
Participants
Subjects will be recruited from University and community
practitioners, as well as through media advertisements.
Enrollment and treatment will be conducted in clinical/la-
boratory facilities at the University of Utah’s Rocky Moun-
tain Center for Occupational and Environmental Health.
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tional review board (IRB) approved study marketing ma-
terials will be screened based on inclusion and exclusion
criteria. If all criteria are met, they will be scheduled for
a consent, randomization, and initial treatment.
Inclusion criteria for study eligibility includes: ages
18–65 with chronic low back pain (≥3 months duration;
a current VAS pain rating ≥5/10; no radiating pain below
the knee; ≥75% back or buttock pain rather than lower
extremity pain; English speaking, and able to complete
and tolerate treatment for the study period.
Exclusion criteria include: Prior home use of H-WaveW
Device or TENS. Prior history of spinal fusion or failed
spinal surgery syndrome. Laminectomy, laminotomy or
discectomy within 12 months of enrollment. Diagnostic or
interventional injections or any low back surgeries not
mentioned above, including radiofrequency neuroablation
within 6 months of enrollment. Current implanted cardiac
demand pacemakers, defibrillators, cardiac pumps, spinal
stimulators or other implanted electronic devices. Patients
using personal home based electrical stimulation devices
are excluded to reduce risk of blinding failure. Patients
with other concomitant illnesses (e.g., malignancy, osteo-
porosis) which, in the opinion of the investigator, wouldFigure 1 Trial design, procedures, stages and data collection.preclude successful patient participation will also be
excluded. Active psychiatric disorders will be excluded
(e.g. use of antipsychotic medication, bipolar disorder,
schizophrenia). Patients diagnosed with history of signifi-
cant mood disorder will be excluded (e.g., depression or
anxiety with adequate control would be acceptable). Pa-
tients currently are or who become pregnant will be
excluded.
Consent will be obtained prior to randomization. Po-
tential study subjects will be given a copy of the consent
document and the document will be outlined in detail
by a research team member. Potential study subjects will
be given opportunities to ask questions prior to signing
the consent form and enrolling in the study.
This study has been approved through the University
of Utah Institutional Review Board (IRB # 52918). Study
participants will receive compensation for participation
in this study (Figure 1).
Randomization and allocation procedures
Subjects will be allocated through central, computerized
randomization utilizing a stratified permuted-block
randomization employing random block sizes. After
confirming eligibility and completion of baseline data
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nated investigator (MST) for allocation. He will consult
the prepared block randomized list and the next alloca-
tion contained in sealed opaque envelope will be given
to the treatment provider, while also recording the sub-
ject ID number to allow for ascertainment of compli-
ance with treatment allocation. The three treatment
arms are labeled using letters “L”, “W” and “E” and
correspond to a labeled device. The names of particular
devices will not be used. The treatment provider will
open the envelope and provide the assigned treatment
device to the participant. Block stratification will be
performed for opioid use (current vs. past/never) and
workers’ compensation claim (yes vs. no).
Blinding
We will attempt to blind patients and assessors to
achieve double blinding. Patients will not be told what
electrotherapy techniques are being utilized in this
study, only that there are two active electrotherapies out
of the spectrum of electrotherapy devices and a sham
group. All study materials will be void of the words H-
WaveW or TENS. Patient blinding will be accomplished
by providing all patients either a H-WaveW device, a
fully operation TENS Unit modified to function within a
H-WaveW device housing, or a sham electrotherapy de-
vice with minimally perceptible electrical current output
modified to function within a H-WaveW device housing.
Researchers providing the treatment are not blinded. As-
sessors are blinded and will not be present for the inter-
vention. Participants will be instructed not to reveal or
discuss the type of treatment characteristics they are
experiencing.
Sham devices will appear to operate in the same exact
way as a fully functional electrotherapy device, including
battery drain and usage log. At maximal settings, weak
electrical current will be flowing to the pads so that the
patients may perceive the device as active treatment.
Additional blinding of subjects or treatment within
this trial is not possible. The research team will be re-
quired to wear color-coded nametags indicating whether
or not the researcher is blinded or non-blinded to avoid
any confusion at the time of assessments. Efficacy of as-
sessor blinding will be conducted at all onsite assess-
ments by recording assessor’s opinion of treatment arm
for each subject.
Outcome measures
Outcome measures will be assessed at baseline, 1 week,
4 weeks, 8 weeks, and 12 weeks, with the primary out-
come being at 4 weeks. Assessment will occur in the same
manner and at the same time intervals for all treatment
arms utilizing standardized methods. Treatment failure
will be defined as if patient terminates assigned treatmentarm for non-efficacy or election to pursue surgical or inva-
sive procedure or other excluded cointerventions.
The primary outcome measure will be the Oswestry
Disability Index (ODI). The ODI is widely used in low
back pain intervention trials, and provides a measure of
functional improvement The ODI was selected com-
pared to a subjective pain rating [25-29]. Secondary out-
come measures include Rowland Morris Instrument
(0–24 scale of disability); VAS Pain score (0–100); phys-
ical activity levels objectively measured using accelerom-
eters worn by participants during waking hours over
during the entire 12 week study period; functional cap-
acity evaluation including strength when pushing and
pulling (3 repetitions lasting 5 seconds each of both
pushing and pulling measuring both peak and average
kg of force according to standard EvalTech Functional
Systems protocol which utilizes a load cell to measure
forces exerted); range of lumbar spine motion (up to parti-
cipants maximum range of specific movement) in flexion,
extension, lateral rotation; duration of time (minutes) sit-
ting comfortably (subjective estimate made by participant
during questionnaire); duration of time (minutes) standing
comfortably (subjective estimate made by participant
during questionnaire); duration (minutes) and distance
(meters) walking comfortably (subjective estimate made
by participant during questionnaire); summed VAS pain ×
days rating; days of impairment (days); lost workdays
(days); time to exacerbation (days until increase 3/10
pain); rescue acetaminophen tablets consumed (% and
number); NSAID discontinuation (%); opioid discontinu-
ation (%). The pain VAS score is assessed immediately be-
fore and after treatment at weeks 0, 1, and daily scores pre
and post home-treatment in a diary that the participant
keeps (Table 1).
Functional assessments will be completed using a stan-
dardized protocol on a BTE EvalTech system. Standard
protocols for Lumbar Flexion/Extension, Lumbar Lateral
Flexion, Shoulder Height Push and Pull, Cart Height Push
and Pull are used. Researchers performing assessments
are trained to perform all assessments exactly the same
following the BTE EvalTtech protocol (Figure 2).
Subjective outcomes data will be collected using com-
puterized data collection tools utilizing Filemaker ProTM
database management to assure complete and accurate
data collection. Data will be collected at enrollment and
subsequent treatments. Data after treatments end will be
collected in person using the same tools for every par-
ticipant study by a blinded assessor.
Assessments
Timing of assessments is identical in each arm. Assess-
ments will be conducted by blinded assessors. Enrollment,
randomization and initial treatment will occur at the time
of enrollment. All participants will return 1 week after
Table 1 Outcome measures
Primary outcome measure:
Oswestry Disability Index (ODI)
Secondary measures:
a. Rowland Morris Instrument (0–24 scale of disability)
b. VAS Pain score (0–10)
c. Physical activity levels (objectively measured using accelerometers)
d. Functional evaluation including strength when pushing (peak and
average kg of force)
e. Functional evaluation including strength when pulling (peak and
average kg of force)
f. Comfortable (up to maximum baseline pain level) range of motion
in flexion (degrees from neutral)
g. Comfortable (up to maximum baseline pain level) range of motion
in extension (degrees from neutral)
h. Duration of time sitting comfortably (up to maximum baseline pain
level) (minutes)
i. Duration of time standing comfortably (up to maximum baseline
pain level) (minutes)
j. Duration and distance walking comfortably (up to maximum
baseline pain level) (minutes and meters)
k. Summed VAS pain × days rating
l. Days of impairment (days)
m. Lost workdays (days)
n. Time to exacerbation (days until increase 3/10 pain)
o. Rescue acetaminophen tablets consumed (% and number)
p. NSAID discontinuation (%)
q. Opioid discontinuation (%)
Figure 2 Shoulder height push assessment using BTE
EvalTech system.
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rectly use their assigned device; have questions answered
about the protocol, and to complete week 1 assessment.
Subjective assessments will be measured at baseline, 1 -
week, 4 weeks, 8 weeks, and 12 weeks. Objective assess-
ments will be measured pre and post-treatment at
baseline and post-treatment at week 1, week 4, and week
12. No treatments are provided by the researchers after
week 1, although patients will be performing home treat-
ments per protocol for the entire 12 week period. Compli-
ance will be assessed using digital time data logs recorded
automatically by each device and diaries kept by partici-
pants. Participants in each arm will have identical and
comparable contact time with providers and assessors to
minimize treatment bias. All participants will be contacted
weekly by a blinded assessor via telephone to encourage
compliance and use of daily treatment diaries.
At each assessment, all participants receive the same
assessment, including questionnaire, physical functio-
ning assessment form, and recording of accelerometer
use. All measures will be assessed using computerized
data collection methods at baseline and each follow-up,
except at the 8-week follow-up where outcomes will be
assessed over the phone. There are four objectivemeasures which are assessed via electronic device
(Actigraph GT3X + Accelerometers and EvalTech func-
tional testing equipment manufactured by BTE Tech-
nologies). The accelerometers provide physical activity
levels on a per minute basis and store up to 40 days of
data. These accelerometers have demonstrated validity
and reliability in a variety of settings [30-38]. Functional
strength and lumbar range of motion will be captured
using EvalTech functional evaluation tools. These in-
clude fully modifiable load cells allowing different
heights, widths, and orientations, as well as electronic
range of motion devices for adequate capture. All trials
will be performed 3 times. Pushing and pulling strength
will be three trials each with exertions for 5 seconds and
a 20 second break between trials. These will be at both
shoulder height and cart height (approximately 49
inches). There will be a minimum of 6 trials (3 push and
3 pull at both shoulder height and cart height). Peak and
average forces will be recorded for each trial.
Treatment protocols
Subjects will be allocated to one of the three arms. Each
treatment arm will have identical numbers of visits and
contact time. Each arm will receive the uniform ins-
tructions for using of their assigned electrotherapy device.
Patients will be instructed to use their assigned device
daily upon waking and before bedtime, and up to two add-
itional treatments during the day as needed (e.g., 4 1-hour
treatment sessions). Providers will place electrodes and
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Patients will be told that it is possible to not immediately
feel effects of electrical treatment due to current levels
that do not meet sensory thresholds. Patients will return
after 1 week for reevaluation on electrode placement and
ability to achieve the required self-administered stimula-
tion levels. Providers are trained in standardized fashion
to educate each participant on their assigned therapy.
The H-WaveW device delivers electrical stimulation
through the placement of 4 electrode pads in a rectangu-
lar geometric pattern at the circumference of the low
back pain nidus. Patients will be instructed on optimal
electrode placement for home use. The H-WaveW Device
is controlled by the patient after instruction from a ther-
apist or practitioner. The stimulation parameters in
terms of pulse duration and frequency are proprietary
for the manufacturer and thus are not included in this
protocol. However, the maximal intensity offered by the
device is the goal of the treatment intensity. Patients are
instructed to achieve the highest intensity possible in
graduated fashion. Lower intensities are accepted if the
patient cannot comfortably reach the maximal device
intensity and will be noted on diary logs. There are con-
trols for intensity and frequency, which the patient
manipulates according to specific instructions and toler-
ances. Patients in this arm will be required to reach near
maximal intensity on low frequency. The maximal inten-
sity may, in rare cases, induce transient muscular con-
tractions. Patients are instructed not to increase the
intensity to a painful level. The treatment is then self-
administered for the duration of the study.
There are no accepted standardized protocols found in
the literature for TENs treatment of chronic low back
pain. There are no trials that demonstrate maximum ef-
ficacy of pulse duration, wave type, or frequency. There-
fore, the TENS units in this study allow adjustment of
amplitude (intensity) only at a fixed frequency of 100 Hz
with steady state pulsing. Modulation and pulse modes
will be disabled in order to maintain uniformity of elec-
trotherapy protocols. Pad placement will be directed by
the provider to provide maximal clinical efficacy. The
device is two channel TENS and will be administered by
the patient after training by the provider.
The sham or control device will appear to operate in
the same exact way as a fully functional TENS device,
including battery drain and usage log. Subtherapeutic
electrical current will be flowing to the pads so that the
patient may perceive it as an active therapy. They will be
instructed to use the device for the same duration as ac-
tive treatments, daily upon waking and before bedtime,
and up to two additional treatments during the day as
needed (e.g., 4 1-hour treatment sessions). There is no
quality evidence that subtherapeutic electrical current
provides any clinical benefit over no electrotherapyeffectiveness for LBP, however this will likely blind the
patients because none of them have ever experienced
the H-Wave Device. Blinding of patients is achieved as
none will have previously experienced H-Wave, home
based TENS therapy, or subtherapeutic electrotherapy.
Further, patients are kept blind as to which electrother-
apy devices out of the myriad devices on the market, are
included in the study and therefore have few precon-
ceived notions to their assigned device.
Compliance
Compliance will be assessed by device logs and diaries.
Each device will be capable of recording treatment appli-
cations and duration, and will be downloaded electronic-
ally at each in-person assessment. Total treatment time
of 3.5 hours per week will be set as the threshold for
compliance. If VAS Pain drops to a daily average of less
than or equal to 2 out of 10, patients will be considered
in compliance regardless of the number of treatments
completed on that day. Patients will be called once per
week to promote compliance and answer any questions.
Discontinuation
Subjects will be encouraged to continue to follow-up
throughout the study. There are no penalties for early
dropouts other than the amount of incentive earned is
reduced if the entire follow-up period is not completed.
Each device (H-WaveW, TENS) has very low adverse ef-
fect profile. Although unexpected, those developing an
adverse event will be reported to the IRB.
Usual care and co-interventions
Study participants will be asked to avoid significant
changes in medical/healthcare management of their LBP
during the study period. All participants will be allowed
to pursue usual care with their own personal treating
physician. No other treatment other than the assigned
electrotherapy intervention will be provided by the trial
researchers. Usual care will be limited to non-invasive
therapies, including medications such as NSAIDS (pre-
scription or over the counter) and opioids, physical
therapy, manipulation, stretching and aerobic exercise.
Self-applications of heat or ice are also acceptable. All
usual care medications and interventions will be recorded.
Interventions not allowed
Any lumbosacral invasive procedure such as discectomy,
microdiscetomy, laminectomy, lumbar fusion, disc desic-
cation by any chemical or thermal means. No injections
into the lumbosacral area other than localized trigger
point without the use of glucocorticoids. No other elec-
trical therapies (PENS, Interferential therapy). No use of
oral or systemic glucocorticosteroids. TENS and H-WaveW
are not allowed except in the arms assigned to those
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Sample size determination is based on the comparisons
of the study arms for the primary outcome variable,
ODI. In previous studies of low back pain patients , the
baseline ODI values for one study group were mean
(SD) of 60.2 (15.0) and for a second study group were
59.9 (14.4) [39,40]. The total score for the ODI is a per-
centage, ranging from 0 to 100. It is suggested that the
reliability of the ODI requires a minimum detectable
change of at least 10 points, as any smaller difference
may be attributable to error in the measurement [25].
Assuming equality of the study arms at baseline, which
can be assured by adjusting for baseline ODI in the re-
gression model, and a minimal detectable effect size of a
10 point difference on the post-treatment value, sample
size is based on a comparison of mean (SD) of 60 (15)
vs. 50 (15), a 17% relative difference post treatment,
using a two-sided comparison with alpha of 0.025 to
allow for multiplicity adjustment. Under these assump-
tions, a sample size of n = 43 subjects per study arm is
required to achieve 80% power. However, it is expected
that the stimulation arms will produce at least a 25%
relative improvement over the control arm. Assuming
60 (15) vs. 45 (15), a 25% relative difference, using a
two-sided alpha 0.025 comparison, a sample size of n =
20 subjects per study arm is required for 80% power, or
n = 25 subjects for 90% power. Allowing for a 20% drop-
out rate, a sample size of n = 38 subjects will be enrolled




The primary analysis is the comparison of the three
study arms on the primary outcome, Oswestry Disability
Index (ODI). Given that repeated measurements are col-
lected, a mixed effects linear regression model will be fit-
ted with an unstructured covariance matrix to account
for lack of independence introduced by the repeated
measurements. In this model, the repeated measure-
ments are nested within study subject (weeks 0, or base-
line, and weeks 1, 4, 8, and 12). The primary predictor is
study group. A time variable will be included as a covari-
ate, since visits will not always be at the planned inter-
vals. Other covariates will be assessed for possible
confounding in the relationship between treatment arm
and outcome. It is likely that the pattern of dropouts will
vary between the study groups, where the study inter-
ventions that are most effective having the dropoutslater on in the follow-up, while the intervention least
effective to have dropouts early on. The analysis will
emphasize the 4-week time point as the primary end
point, which ends the intensive intervention period. At
4 weeks compliance to the protocol and complete
follow-up should be at a maximum. The remaining time
to 12 weeks will measure long term effectiveness and ac-
ceptance of the study interventions.
Secondary analyses
The changes from baseline to each follow-up visit in the
pain VAS (the main secondary endpoint) will be ana-
lyzed using the same longitudinal model described above
for the Oswestry score. Key secondary comparisons will
include the three pair wise comparisons between the
treatment groups in the mean change in the Roland
Morris Instrument, VAS, strength, and flexibility mea-
sures at the different time points.,
The changes to 12 weeks will evaluate the persistence
of treatment effects of the interventions to that time;
changes to 4 weeks evaluate treatment effects at the
completion of the intensive intervention period, and the
slopes from weeks 4 to 12 evaluate changes in the treat-
ment effects after 4 weeks. The null hypothesis is that
there is no difference between the three treatment arms
at 12 weeks.
Intent-to-treat analysis
These data will be analyzed using an intent-to-treat ana-
lysis. As H-WaveW Device is not widely utilized in study
catchment area it is doubtful that individuals will inad-
vertently crossover to that arm from the controls. How-
ever, that possibility will be both discouraged and
tracked.
Multiplicity
A multiplicity adjustment will be made for the compari-
son of the primary outcome variable, Oswestry Disability
Index (ODI). The two-sided p values from the hypoth-
esis tests will be adjusted for two comparisons using the
Hochberg procedure [41]. With that procedure, the
smaller of the two p values is compared against alpha =
0.025 and the larger p value is compared against alpha =
0.05. This maintains the overall alpha at 0.05 for the ef-
fectiveness win strategy evaluation.
Co-variates
Age, gender, tobacco, undiagnosed anxiety, undiagnosed
depression, past back pain history, prior and current
NSAID use, rescue acetaminophen use.
Post-hoc analyses
Post-hoc analyses will be conducted to attempt to ascer-
tain what factors predicted better responders among the
Thiese et al. BMC Musculoskeletal Disorders 2013, 14:117 Page 8 of 9
http://www.biomedcentral.com/1471-2474/14/117two treatment arms. Potential prognostic factors include
gender, tobacco, anxiety, depression, (age and past back
pain history will be assessed for residual confounding,
but controlled in study design), belief in effectiveness of
the treatments, NSAID use, rescue acetaminophen use.
Other considerations
The primary and main secondary analyses will be per-
formed using an intent-to-treat strategy in which patients
are analyzed based on their randomized assignment irre-
spective of their compliance to the treatment protocol.
Formal interim analyses of efficacy will not be conducted.
However, the operational aspects of the study (recruit-
ment, retention, adherence rates, and rates of missed
visits) will be monitored as the study progresses so that
corrective action may be taken to address any unexpec-
ted difficulties. Monitoring for safety will be conducted
throughout the study, investigating all possible unantici-
pated safety events, including increased pain and discom-
fort which are the two most likely types of events to
occur. These treatments are widely used and are consid-
ered safe with low rates of adverse effects. Efforts will be
made to minimize the rates of missing data, including
telephone follow-up of missed visits. The restricted max-
imum likelihood procedure of the primary analysis pro-
duces approximately unbiased estimates of the treatment
effects so long as data are missing at random [42] and is
less sensitive to missing data than analyses restricting to
complete data [43]. In sensitivity analyses, multiple imput-
ation incorporating baseline and follow-up predictors of
outcome [44] will be used to assess the effect of potential
violations of the missing at random assumption.
Discussion
Chronic low back pain is a significant issue, resulting in
significant costs, lost productivity, and morbidity [1-6].
Therefore, even small improvements in treatment effi-
cacy, particularly for treatments with few side effects,
can have a meaningful impact on improving LBP. While
there have been some studies assessing the therapeutic
effectiveness of TENS, the effect generally is relatively
small improvements in chronic LBP as compared to
sham treatment. The use of two comparison arms in this
study, both TENS and sham treatment, allows for com-
parisons of experimental device with both TENS as well
as sham treatment.
Blinding within this study is a significant strength.
All devices are identical in appearance, weight, display,
charge time, and sound. It is anticipated that complete
blinding of the assessors and patients will be achieved.
Care will be taken to limit contact between participants,
e.g. schedule participants one at a time so they are not
waiting in the same room together. All treatment ques-
tions will be directed to the interventionalists, as tomaintain blinding of the assessors. Additionally, this
protocol outlines concealing the treatment allocation by
using opaque envelopes that appear identical. The utili-
zation of a complex randomization schedule is another
strength that may ensure equality of treatment groups at
baseline. The intent-to-treat analysis may account for
unequal dropout between groups and any contamination
that may occur.
Potential weaknesses include the possibility of high
dropout in one or more treatment arm. To combat this,
we are offering incentives and encouraging participants
to continue for the entire duration of the study. There is
the possibility of a randomization failure, which cannot
be overcome. Additionally, due to the nature of the
treatment, specifically the differences between the ex-
perimental treatment and the TENS treatment, it was
not feasible to blind the interventionalist. To address
this all interventionalists will undergo strict training and
re-standardization based on the treatment protocol. This
training will stress treating all patients similarly with
regards to demeanor and contact time, regardless of
their randomized treatment arm.
Endnotes
a Based on the ACOEM criteria, this study protocol is
intended to provide a high-quality score (Randomization –
1, Blinded Allocation – 1, Baseline Comparability – 1, Pa-
tient blinding – 1, Interventionist blinding – 0, Assessor
Blinding – 1, Control of co-interventions – 0.5, Compli-
ance – 1.0, Drop Out < 20% – 1, Timing of assessments –
1, ITTanalysis – 1 (Total score 9.5/11) High-quality ≥ 8.0.
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